The number of high-risk factors is related to outcome in stage II colonic cancer patients
Abstract Background A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-...
Saved in:
Published in | European journal of surgical oncology Vol. 37; no. 11; pp. 964 - 970 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.11.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Background A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-4N+M0) colonic cancer and it is therefore strongly advised to treat them with adjuvant chemotherapy. The purpose of this study was i) to determine the magnitude of prognostic significance of the conventional high-risk factors and ii) to determine whether the number of high-risk factors influences outcome. Methods We retrospectively analyzed 212 stage II colonic cancer patients undergoing surgery between January 2002 and December 2008. No adjuvant chemotherapy was given. Survival analyses were performed. Results 154/212 (73%) patients were considered to be high-risk patients based on conventional high-risk factors. 58 patients did not meet any high-risk factor, 125 patients met 1 high-risk factor and 29 patients met ≥2 high-risk factors. Median follow up was 40 months. Multivariate analysis identified four independent risk factors for recurrent/metastatic disease: age, obstruction, perforation and lymphangio-invasion. The three-year-DFS-rates for the low-risk group, the high-risk group with 1 high-risk factor and the high-risk group with ≥2 high-risk criteria are 90.4%, 87.6% and 75.9% respectively. Patients meeting ≥2 conventional high-risk criteria had a significantly worse three-year disease free survival ( p < 0.002). Conclusions Four independent high-risk factors were identified. The number of high-risk factors does influence outcome. More attention should be given to the definition and treatment of high-risk stage II colonic cancer patients. |
---|---|
AbstractList | BACKGROUNDA subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-4N+M0) colonic cancer and it is therefore strongly advised to treat them with adjuvant chemotherapy. The purpose of this study was i) to determine the magnitude of prognostic significance of the conventional high-risk factors and ii) to determine whether the number of high-risk factors influences outcome.METHODSWe retrospectively analyzed 212 stage II colonic cancer patients undergoing surgery between January 2002 and December 2008. No adjuvant chemotherapy was given. Survival analyses were performed.RESULTS154/212 (73%) patients were considered to be high-risk patients based on conventional high-risk factors. 58 patients did not meet any high-risk factor, 125 patients met 1 high-risk factor and 29 patients met ≥2 high-risk factors. Median follow up was 40 months. Multivariate analysis identified four independent risk factors for recurrent/metastatic disease: age, obstruction, perforation and lymphangio-invasion. The three-year-DFS-rates for the low-risk group, the high-risk group with 1 high-risk factor and the high-risk group with ≥2 high-risk criteria are 90.4%, 87.6% and 75.9% respectively. Patients meeting ≥2 conventional high-risk criteria had a significantly worse three-year disease free survival (p < 0.002).CONCLUSIONSFour independent high-risk factors were identified. The number of high-risk factors does influence outcome. More attention should be given to the definition and treatment of high-risk stage II colonic cancer patients. A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-4N+M0) colonic cancer and it is therefore strongly advised to treat them with adjuvant chemotherapy. The purpose of this study was i) to determine the magnitude of prognostic significance of the conventional high-risk factors and ii) to determine whether the number of high-risk factors influences outcome. We retrospectively analyzed 212 stage II colonic cancer patients undergoing surgery between January 2002 and December 2008. No adjuvant chemotherapy was given. Survival analyses were performed. 154/212 (73%) patients were considered to be high-risk patients based on conventional high-risk factors. 58 patients did not meet any high-risk factor, 125 patients met 1 high-risk factor and 29 patients met ≥2 high-risk factors. Median follow up was 40 months. Multivariate analysis identified four independent risk factors for recurrent/metastatic disease: age, obstruction, perforation and lymphangio-invasion. The three-year-DFS-rates for the low-risk group, the high-risk group with 1 high-risk factor and the high-risk group with ≥2 high-risk criteria are 90.4%, 87.6% and 75.9% respectively. Patients meeting ≥2 conventional high-risk criteria had a significantly worse three-year disease free survival ( p < 0.002). Four independent high-risk factors were identified. The number of high-risk factors does influence outcome. More attention should be given to the definition and treatment of high-risk stage II colonic cancer patients. Abstract Background A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-4N+M0) colonic cancer and it is therefore strongly advised to treat them with adjuvant chemotherapy. The purpose of this study was i) to determine the magnitude of prognostic significance of the conventional high-risk factors and ii) to determine whether the number of high-risk factors influences outcome. Methods We retrospectively analyzed 212 stage II colonic cancer patients undergoing surgery between January 2002 and December 2008. No adjuvant chemotherapy was given. Survival analyses were performed. Results 154/212 (73%) patients were considered to be high-risk patients based on conventional high-risk factors. 58 patients did not meet any high-risk factor, 125 patients met 1 high-risk factor and 29 patients met ≥2 high-risk factors. Median follow up was 40 months. Multivariate analysis identified four independent risk factors for recurrent/metastatic disease: age, obstruction, perforation and lymphangio-invasion. The three-year-DFS-rates for the low-risk group, the high-risk group with 1 high-risk factor and the high-risk group with ≥2 high-risk criteria are 90.4%, 87.6% and 75.9% respectively. Patients meeting ≥2 conventional high-risk criteria had a significantly worse three-year disease free survival ( p < 0.002). Conclusions Four independent high-risk factors were identified. The number of high-risk factors does influence outcome. More attention should be given to the definition and treatment of high-risk stage II colonic cancer patients. A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2) <10 lymph nodes 3) T4 lesions and 4) lymphangio-invasion. Their prognosis is regarded as comparable to stage III (T1-4N+M0) colonic cancer and it is therefore strongly advised to treat them with adjuvant chemotherapy. The purpose of this study was i) to determine the magnitude of prognostic significance of the conventional high-risk factors and ii) to determine whether the number of high-risk factors influences outcome. We retrospectively analyzed 212 stage II colonic cancer patients undergoing surgery between January 2002 and December 2008. No adjuvant chemotherapy was given. Survival analyses were performed. 154/212 (73%) patients were considered to be high-risk patients based on conventional high-risk factors. 58 patients did not meet any high-risk factor, 125 patients met 1 high-risk factor and 29 patients met ≥2 high-risk factors. Median follow up was 40 months. Multivariate analysis identified four independent risk factors for recurrent/metastatic disease: age, obstruction, perforation and lymphangio-invasion. The three-year-DFS-rates for the low-risk group, the high-risk group with 1 high-risk factor and the high-risk group with ≥2 high-risk criteria are 90.4%, 87.6% and 75.9% respectively. Patients meeting ≥2 conventional high-risk criteria had a significantly worse three-year disease free survival (p < 0.002). Four independent high-risk factors were identified. The number of high-risk factors does influence outcome. More attention should be given to the definition and treatment of high-risk stage II colonic cancer patients. |
Author | Koebrugge, B Lips, D.J van der Linden, J.C Vogelaar, F.J Bosscha, K Pruijt, J.F Ernst, M.F |
Author_xml | – sequence: 1 fullname: Koebrugge, B – sequence: 2 fullname: Vogelaar, F.J – sequence: 3 fullname: Lips, D.J – sequence: 4 fullname: Pruijt, J.F – sequence: 5 fullname: van der Linden, J.C – sequence: 6 fullname: Ernst, M.F – sequence: 7 fullname: Bosscha, K |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21930361$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kTFv1TAUhS1URF8Lf4ABeWNKuI5jJ5EQEqqAPqkSA2Vgshz7ps9pEj9sp1L_PY5eYejAdJdzPul894KcLX5BQt4yKBkw-WEscYy-rICxEtqScfGC7JjgVVEx0ZyRHTR1WzRdy8_JRYwjAHS86V6R84p1HLhkO_Lr9oB0WeceA_UDPbi7QxFcvKeDNsmHSF2kASed0NLkqV-T8TNSt9CY9B3S_Z4aP_nFGWr0YjLlqJPDJcXX5OWgp4hvnu4l-fn1y-3VdXHz_dv-6vNNYepGpqKSjWm5bSoNrbS21nwQvbaCy9pqyU1vatE1QjJoaw4oetnD0DHBGtu12AO_JO9P3GPwv1eMSc0uGpwmvaBfo-ryUMl5K3OyOiVN8DEGHNQxuFmHR8VAbUbVqDajajOqoFXZaC69e8Kv_Yz2X-Wvwhz4eApgHvngMKhosgCD1gU0SVnv_s__9KxuJpd16ukeHzGOfg1L1qeYipUC9WP76fZSxgAEZxX_AxG9nUM |
CitedBy_id | crossref_primary_10_1245_s10434_014_3820_5 crossref_primary_10_1007_s00384_012_1563_y crossref_primary_10_5301_jbm_5000255 crossref_primary_10_1016_j_ejso_2017_04_012 crossref_primary_10_1136_bmjopen_2014_005012 crossref_primary_10_1530_ERC_13_0351 crossref_primary_10_1016_j_prp_2020_153034 crossref_primary_10_1097_DCR_0000000000000124 crossref_primary_10_1097_SLA_0000000000006145 |
Cites_doi | 10.1136/gut.2006.116830 10.1007/s00384-009-0634-1 10.1200/JCO.1999.17.5.1356 10.1136/gut.51.1.65 10.1002/jso.10140 10.1200/JCO.2004.09.059 10.1200/JCO.2007.15.9434 10.1007/s00268-001-0236-8 10.1016/j.ejso.2008.07.011 10.1007/s00595-009-4047-0 10.1093/jnci/djh275 10.1007/s00384-006-0262-y 10.1097/SLA.0b013e3181f19767 10.1007/PL00012376 10.1007/DCR.0b013e3181979164 10.1007/s10350-008-9246-z 10.1002/bjs.7254 10.1245/s10434-006-9120-y |
ContentType | Journal Article |
Copyright | Elsevier Ltd 2011 Elsevier Ltd Copyright © 2011 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: Elsevier Ltd – notice: 2011 Elsevier Ltd – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ejso.2011.08.135 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-2157 |
EndPage | 970 |
ExternalDocumentID | 10_1016_j_ejso_2011_08_135 21930361 S0748798311005312 1_s2_0_S0748798311005312 |
Genre | Journal Article Comparative Study |
GeographicLocations | Netherlands |
GeographicLocations_xml | – name: Netherlands |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO ABBQC ABFNM ABMAC ABMZM ABXDB ACDAQ ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N9A O-L O9- OAUVE OK- OW- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 X7M Z5R ZGI ZXP ~G- AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c476t-267c83d72a086dd4a3f5bad5364da63cbc459756108430e5b6b0f91517d98eb03 |
IEDL.DBID | .~1 |
ISSN | 0748-7983 |
IngestDate | Sat Oct 26 00:00:34 EDT 2024 Thu Sep 26 18:04:43 EDT 2024 Sat Sep 28 08:01:39 EDT 2024 Fri Feb 23 02:26:36 EST 2024 Tue Oct 15 22:56:40 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Chemotherapy Treatment Colonic cancer Survival Outcome High-risk |
Language | English |
License | Copyright © 2011 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c476t-267c83d72a086dd4a3f5bad5364da63cbc459756108430e5b6b0f91517d98eb03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21930361 |
PQID | 903663386 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_903663386 crossref_primary_10_1016_j_ejso_2011_08_135 pubmed_primary_21930361 elsevier_sciencedirect_doi_10_1016_j_ejso_2011_08_135 elsevier_clinicalkeyesjournals_1_s2_0_S0748798311005312 |
PublicationCentury | 2000 |
PublicationDate | 2011-11-01 |
PublicationDateYYYYMMDD | 2011-11-01 |
PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | European journal of surgical oncology |
PublicationTitleAlternate | Eur J Surg Oncol |
PublicationYear | 2011 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Cianchi, Palomba, Boddi (bib13) 2002; 26 van Schaik, Hermans, van der Linden, Pruijt, Ernst, Bosscha (bib21) 2009; 35 Kelder, Inberg, Schaapveld (bib11) 2009; 52 Bilchik, Nissan, Wainberg (bib22) 2010; 252 Tan, Konishi, Suzuki (bib8) 2010; 40 Lin, Lin, Chang (bib15) 2009; 24 Registry of federally and privately supported clinical trials. Association of Comprehensive Cancer Centres. . Quah, Chou, Gonen (bib6) 2008; 51 Petersen, Baxter, Love, Shepherd (bib3) 2002; 51 Horgan, McMilan (bib23) 2010; 97 O'Connell, Maggard, Ko (bib14) 2004; 96 Iddings, Ahmad, Elashoff, Bilchik (bib20) 2006; 13 Keating, Landrum, Klabunde (bib9) 2008 May 20; 26 Cserni, Vinh-Hung, Burzykowski (bib12) 2002; 81 Morris, Platell, McCaul (bib7) 2007; 22 (bib19) 2007; 37 Morris, Maughan, Forman, Quirke (bib4) 2007; 56 (bib2) 2008 Park, Park, Park, Lee, Choe, Kim (bib5) 1999; 23 Gill, Loprinzi, Sargent (bib18) 2004; 22 ASCO guideline colonic cancer. (bib17) 1999; 17 Lin (10.1016/j.ejso.2011.08.135_bib15) 2009; 24 Morris (10.1016/j.ejso.2011.08.135_bib4) 2007; 56 10.1016/j.ejso.2011.08.135_bib10 (10.1016/j.ejso.2011.08.135_bib2) 2008 O'Connell (10.1016/j.ejso.2011.08.135_bib14) 2004; 96 Quah (10.1016/j.ejso.2011.08.135_bib6) 2008; 51 Petersen (10.1016/j.ejso.2011.08.135_bib3) 2002; 51 Cianchi (10.1016/j.ejso.2011.08.135_bib13) 2002; 26 Bilchik (10.1016/j.ejso.2011.08.135_bib22) 2010; 252 10.1016/j.ejso.2011.08.135_bib1 Tan (10.1016/j.ejso.2011.08.135_bib8) 2010; 40 (10.1016/j.ejso.2011.08.135_bib19) 2007; 37 Iddings (10.1016/j.ejso.2011.08.135_bib20) 2006; 13 Keating (10.1016/j.ejso.2011.08.135_bib9) 2008; 26 (10.1016/j.ejso.2011.08.135_bib17) 1999; 17 van Schaik (10.1016/j.ejso.2011.08.135_bib21) 2009; 35 Morris (10.1016/j.ejso.2011.08.135_bib7) 2007; 22 Cserni (10.1016/j.ejso.2011.08.135_bib12) 2002; 81 Horgan (10.1016/j.ejso.2011.08.135_bib23) 2010; 97 Park (10.1016/j.ejso.2011.08.135_bib5) 1999; 23 Kelder (10.1016/j.ejso.2011.08.135_bib11) 2009; 52 10.1016/j.ejso.2011.08.135_bib16 Gill (10.1016/j.ejso.2011.08.135_bib18) 2004; 22 |
References_xml | – volume: 81 start-page: 63 year: 2002 end-page: 69 ident: bib12 article-title: Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas? publication-title: J Surg Oncol contributor: fullname: Burzykowski – volume: 37 start-page: 2020 year: 2007 end-page: 2029 ident: bib19 article-title: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study publication-title: Lancet – volume: 96 start-page: 1420 year: 2004 end-page: 1425 ident: bib14 article-title: Colon cancer survival rates with the new American joint committee on cancer sixt editing staging publication-title: J Nat Cancer Inst contributor: fullname: Ko – volume: 13 start-page: 1386 year: 2006 end-page: 1392 ident: bib20 article-title: The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta- analysis publication-title: Ann Surg Oncol contributor: fullname: Bilchik – year: 2008 ident: bib2 article-title: Dutch guideline ‘Colonic cancer’ – volume: 52 start-page: 260 year: 2009 end-page: 267 ident: bib11 article-title: Impact of the number of histologically examined lymph nodes on prognosis in colon cancer; a population-based study in the Netherlands publication-title: Dis Colon Rectum contributor: fullname: Schaapveld – volume: 35 start-page: 492 year: 2009 end-page: 496 ident: bib21 article-title: Micro-metastases in stages I and II colon cancer are a predictor of the development of distant metastases and worse disease-free survival publication-title: Eur J Surg Oncol contributor: fullname: Bosscha – volume: 252 start-page: 467 year: 2010 end-page: 476 ident: bib22 article-title: Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer publication-title: Ann Surg contributor: fullname: Wainberg – volume: 23 start-page: 721 year: 1999 end-page: 726 ident: bib5 article-title: Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases publication-title: World J Surg contributor: fullname: Kim – volume: 24 start-page: 665 year: 2009 end-page: 767 ident: bib15 article-title: Is adjuvant therapy beneficial to high risk stage II colon cancer? Analysis in a single institute publication-title: Int J Colorectal Dis contributor: fullname: Chang – volume: 26 start-page: 2532 year: 2008 May 20 end-page: 2537 ident: bib9 article-title: Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? publication-title: J Clin Oncol contributor: fullname: Klabunde – volume: 97 start-page: 1459 year: 2010 end-page: 1460 ident: bib23 article-title: Surgeons and selection of adjuvant therapy for node-negative colonic cancer publication-title: BJS contributor: fullname: McMilan – volume: 22 start-page: 887 year: 2007 end-page: 895 ident: bib7 article-title: Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting publication-title: Int J Colorectal Dis contributor: fullname: McCaul – volume: 26 start-page: 384 year: 2002 end-page: 389 ident: bib13 article-title: Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined publication-title: World J Surg contributor: fullname: Boddi – volume: 17 start-page: 1356 year: 1999 end-page: 1363 ident: bib17 article-title: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer publication-title: J Clin Oncol – volume: 51 start-page: 65 year: 2002 end-page: 69 ident: bib3 article-title: Identification of objective pathological prognostic determinants and models of prognosis in Dukes’B colon cancer publication-title: Gut contributor: fullname: Shepherd – volume: 51 start-page: 503 year: 2008 end-page: 508 ident: bib6 article-title: Identification of patients with high-risk stage II colon cancer for adjuvant therapy publication-title: Dis Colon Rectum contributor: fullname: Gonen – volume: 40 start-page: 385 year: 2010 end-page: 387 ident: bib8 article-title: The evidence for adjuvant treatment of elderly patients (age > or = 70) with stage III colon cancer is inconclusive publication-title: Surg Today contributor: fullname: Suzuki – volume: 22 start-page: 1797 year: 2004 end-page: 1806 ident: bib18 article-title: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? publication-title: J Clin Oncol contributor: fullname: Sargent – volume: 56 start-page: 1419 year: 2007 end-page: 1425 ident: bib4 article-title: Who to treat with adjuvant chemotherapy in Dukes B/stage II colorectal cancer? The need for high quality pathology publication-title: Gut contributor: fullname: Quirke – volume: 56 start-page: 1419 year: 2007 ident: 10.1016/j.ejso.2011.08.135_bib4 article-title: Who to treat with adjuvant chemotherapy in Dukes B/stage II colorectal cancer? The need for high quality pathology publication-title: Gut doi: 10.1136/gut.2006.116830 contributor: fullname: Morris – year: 2008 ident: 10.1016/j.ejso.2011.08.135_bib2 – volume: 24 start-page: 665 year: 2009 ident: 10.1016/j.ejso.2011.08.135_bib15 article-title: Is adjuvant therapy beneficial to high risk stage II colon cancer? Analysis in a single institute publication-title: Int J Colorectal Dis doi: 10.1007/s00384-009-0634-1 contributor: fullname: Lin – volume: 17 start-page: 1356 year: 1999 ident: 10.1016/j.ejso.2011.08.135_bib17 article-title: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.5.1356 – volume: 51 start-page: 65 year: 2002 ident: 10.1016/j.ejso.2011.08.135_bib3 article-title: Identification of objective pathological prognostic determinants and models of prognosis in Dukes’B colon cancer publication-title: Gut doi: 10.1136/gut.51.1.65 contributor: fullname: Petersen – volume: 81 start-page: 63 year: 2002 ident: 10.1016/j.ejso.2011.08.135_bib12 article-title: Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas? publication-title: J Surg Oncol doi: 10.1002/jso.10140 contributor: fullname: Cserni – ident: 10.1016/j.ejso.2011.08.135_bib10 – volume: 22 start-page: 1797 year: 2004 ident: 10.1016/j.ejso.2011.08.135_bib18 article-title: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? publication-title: J Clin Oncol doi: 10.1200/JCO.2004.09.059 contributor: fullname: Gill – volume: 26 start-page: 2532 year: 2008 ident: 10.1016/j.ejso.2011.08.135_bib9 article-title: Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.9434 contributor: fullname: Keating – volume: 37 start-page: 2020 year: 2007 ident: 10.1016/j.ejso.2011.08.135_bib19 article-title: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study publication-title: Lancet – volume: 26 start-page: 384 year: 2002 ident: 10.1016/j.ejso.2011.08.135_bib13 article-title: Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined publication-title: World J Surg doi: 10.1007/s00268-001-0236-8 contributor: fullname: Cianchi – ident: 10.1016/j.ejso.2011.08.135_bib16 – volume: 35 start-page: 492 year: 2009 ident: 10.1016/j.ejso.2011.08.135_bib21 article-title: Micro-metastases in stages I and II colon cancer are a predictor of the development of distant metastases and worse disease-free survival publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2008.07.011 contributor: fullname: van Schaik – volume: 40 start-page: 385 year: 2010 ident: 10.1016/j.ejso.2011.08.135_bib8 article-title: The evidence for adjuvant treatment of elderly patients (age > or = 70) with stage III colon cancer is inconclusive publication-title: Surg Today doi: 10.1007/s00595-009-4047-0 contributor: fullname: Tan – ident: 10.1016/j.ejso.2011.08.135_bib1 – volume: 96 start-page: 1420 year: 2004 ident: 10.1016/j.ejso.2011.08.135_bib14 article-title: Colon cancer survival rates with the new American joint committee on cancer sixt editing staging publication-title: J Nat Cancer Inst doi: 10.1093/jnci/djh275 contributor: fullname: O'Connell – volume: 22 start-page: 887 year: 2007 ident: 10.1016/j.ejso.2011.08.135_bib7 article-title: Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting publication-title: Int J Colorectal Dis doi: 10.1007/s00384-006-0262-y contributor: fullname: Morris – volume: 252 start-page: 467 year: 2010 ident: 10.1016/j.ejso.2011.08.135_bib22 article-title: Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer publication-title: Ann Surg doi: 10.1097/SLA.0b013e3181f19767 contributor: fullname: Bilchik – volume: 23 start-page: 721 year: 1999 ident: 10.1016/j.ejso.2011.08.135_bib5 article-title: Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases publication-title: World J Surg doi: 10.1007/PL00012376 contributor: fullname: Park – volume: 52 start-page: 260 year: 2009 ident: 10.1016/j.ejso.2011.08.135_bib11 article-title: Impact of the number of histologically examined lymph nodes on prognosis in colon cancer; a population-based study in the Netherlands publication-title: Dis Colon Rectum doi: 10.1007/DCR.0b013e3181979164 contributor: fullname: Kelder – volume: 51 start-page: 503 year: 2008 ident: 10.1016/j.ejso.2011.08.135_bib6 article-title: Identification of patients with high-risk stage II colon cancer for adjuvant therapy publication-title: Dis Colon Rectum doi: 10.1007/s10350-008-9246-z contributor: fullname: Quah – volume: 97 start-page: 1459 year: 2010 ident: 10.1016/j.ejso.2011.08.135_bib23 article-title: Surgeons and selection of adjuvant therapy for node-negative colonic cancer publication-title: BJS doi: 10.1002/bjs.7254 contributor: fullname: Horgan – volume: 13 start-page: 1386 year: 2006 ident: 10.1016/j.ejso.2011.08.135_bib20 article-title: The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta- analysis publication-title: Ann Surg Oncol doi: 10.1245/s10434-006-9120-y contributor: fullname: Iddings |
SSID | ssj0009379 |
Score | 2.0718827 |
Snippet | Abstract Background A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour... A subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour obstruction/perforation 2)... BACKGROUNDA subgroup of stage II colonic cancer patients are considered to be at high-risk for recurrent/metastatic disease based on 1) tumour... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 964 |
SubjectTerms | Adult Aged Aged, 80 and over Chemotherapy Colonic cancer Colonic Neoplasms - diagnosis Colonic Neoplasms - epidemiology Colonic Neoplasms - therapy Combined Modality Therapy Female Hematology, Oncology and Palliative Medicine High-risk Hospital Mortality - trends Humans Male Middle Aged Neoplasm Staging Netherlands - epidemiology Outcome Retrospective Studies Risk Assessment - methods Risk Factors Severity of Illness Index Surgery Survival Survival Analysis Survival Rate - trends Treatment |
Title | The number of high-risk factors is related to outcome in stage II colonic cancer patients |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0748798311005312 https://dx.doi.org/10.1016/j.ejso.2011.08.135 https://www.ncbi.nlm.nih.gov/pubmed/21930361 https://search.proquest.com/docview/903663386 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwEB5FqRT1UrVJH9s8NIfcKro8jMHHaNVoN22iqGmk9GSBbSpygCiw1_z2zIDZqGraQ08gBDLMjOcb45lvAI4zq0Lefwkia8pACO4GqFRFZwwoNq5iy8XJ5xdyeS3ObtKbLVhMtTCcVul9_-jTB2_tr8y9NOd3dT2_IvDLM5UnTHpGlsR-WBD8kU1_fnhK81Ceb49uDvhuXzgz5ni5267d0HhGQ8u3Z8Hpb8HnAEKnr-GVjx7xZHzBN7Dlml3YOff743vwk7SOY5MPbCtkLuKAk8fRt9XBusOhesVZ7Fts1z19t8O6QQoSfzlcrZBZrJvaoGFzuEfPu9q9hevTLz8Wy8A3TwiMyGQfxDIzeWKzuKBFi7WiSKq0LGyaSGELmZjSCFpLcPSUiyR0aSnLsFKE_6S93JVh8g62m7ZxHwCVU3GYmtzKkOnMuFlHaYq8cFUksyqNZ_Bpkpq-Gzky9JQ8dqtZxpplrMNck4xnkE2C1VP1J_kr1_nJ0-lId7EO9R8KnkG6efI3G9Hk_v85Ik760zR5eEekaFy77rQi_Ja0SJczeD_qdfMB5MkZ3aOP_znoPrwcfj8PZYsHsN3fr90hxS99eTQY6BG8OFl8_3bJx9XX5cUjHqXt3g |
link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0hkIALKrSFhVLmwK2KNp9OfESoaLewewEkerIS26myhwSR7P9nJnEWVS099BZFsZzMjGee45k3AJepkT6fv3iB0YUXx9wNUMqSrjigmLAMDRcnL5Zi9hj_eEqetuB6rIXhtErn-wef3ntrd2fqpDl9rqrpPQW_LJVZxKRnZEnkh3cIDUhanTtX89vZ8o1711Hu0fMeD3C1M0Oal121zYbJM-i7vv01Pr2HP_s4dPMBDhyAxKvhHQ9hy9ZHsLtwR-Qf4ScpHoc-H9iUyHTEHuePo-usg1WLfQGLNdg12Kw7-nSLVY2EE39ZnM-RiazrSqNmi3hBR73afoLHm-8P1zPP9U_wdJyKzgtFqrPIpGFO-xZj4jwqkyI3SSRik4tIFzqm7QQDqCyOfJsUovBLSRCAFJjZwo8-w3bd1PYEUFoZ-onOjPCZ0Yz7dRQ6z3JbBiItk3AC30apqeeBJkON-WMrxTJWLGPlZ4pkPIF0FKwaC0DJZdnWrZ9WBaoNla_-0PEEks3I38xEUQT454w46k_R-uFDkby2zbpVkkK4oH26mMDxoNfNB5Az5wAfnP7npBewN3tY3Km7-fL2DPb7v9F9FeMX2O5e1vac4ExXfHXm-grhmu79 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+number+of+high-risk+factors+is+related+to+outcome+in+stage+II+colonic+cancer+patients&rft.jtitle=European+journal+of+surgical+oncology&rft.au=Koebrugge%2C+B&rft.au=Vogelaar%2C+F+J&rft.au=Lips%2C+D+J&rft.au=Pruijt%2C+J+F&rft.date=2011-11-01&rft.eissn=1532-2157&rft.volume=37&rft.issue=11&rft.spage=964&rft_id=info:doi/10.1016%2Fj.ejso.2011.08.135&rft_id=info%3Apmid%2F21930361&rft.externalDocID=21930361 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07487983%2FS0748798311X00100%2Fcov150h.gif |